Return on investment has long been a key factor in evaluating packaging systems, equipment, and materials. In a challenging economy, ROI seems an especially logical choice when evaluating isolators and restricted access barrier systems (RABS).
Shedding more light on the role of ROI in this decision-making process is a PharmaManufacturing.com article, “A Business Case for Isolation Technology.” The article cites a Jacobs study, saying, “Though capital costs for isolator-based facilities are higher upfront, they tend to be cheaper in the long run.” A table accompanying the story compares clean room, RABS, and isolator system base costs for various categories, including vial filling and syringe filling.
